预约演示
更新于：2026-05-19
Azelastine Hydrochloride
盐酸氮卓斯汀
更新于：2026-05-19
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C22H25Cl2N3O |
InChIKeyYEJAJYAHJQIWNU-UHFFFAOYSA-N |
CAS号79307-93-0 |
关联
37
项与 盐酸氮卓斯汀 相关的临床试验CTRI/2023/10/059139
A randomized controlled clinical trial to evaluate the efficacy of Anutaila Nasya and Azelastine Nasal Spray in management of Vataj Pratishyaya. - Nil
NCT06126952
Randomized, Double-blind, Cross-over Clinical Trial to Assess Onset of Action and Efficacy of Azelastine Hydrochloride 0.15% Nasal Spray in the Treatment of Allergen-Induced Allergic Rhinitis Symptoms in an Environmental Exposure Unit in Comparison to Placebo and Mometasone Furoate/Olopatadine Hydrochloride Nasal Spray
NCT05887843
An Open-label, Single-Dose, Three-way Crossover Study to Compare the Pharmacokinetics of Fixed-Dose Combination of Mometasone + Azelastine Nasal Spray to Mometasone and Azelastine Nasal Sprays in Adolescents (12 to 17 Years of Age) and Young Adults (18 to 24 Years of Age) With Seasonal Allergic Rhinitis
100 项与 盐酸氮卓斯汀 相关的临床结果
登录后查看更多信息
100 项与 盐酸氮卓斯汀 相关的转化医学
登录后查看更多信息
100 项与 盐酸氮卓斯汀 相关的专利（医药）
登录后查看更多信息
658
项与 盐酸氮卓斯汀 相关的文献（医药）2026-03-01PEDIATRIC ALLERGY AND IMMUNOLOGY
Azelastine‐fluticasone intranasal therapy: A paradigm shift in pediatric allergic rhinitis management. A point of view of the Italian Society of Pediatric Allergy and Immunology
Review
作者: Tosca, Maria Angela ; Ciprandi, Giorgio ; Marseglia, Gianluigi ; Miraglia del Giudice, Michele ; Indolfi, Cristiana ; Licari, Amelia
Abstract:
Background:
Allergic rhinitis (AR) is one of the most prevalent chronic conditions in children and adolescents, significantly impacting quality of life and scholastic performance. Effective management requires therapeutic approaches that address the complex pathophysiology while ensuring safety and tolerability.
Methods:
This paper reviews the evidence supporting azelastine‐fluticasone combination intranasal therapy in pediatric allergic rhinitis, with a focus on efficacy, safety, and clinical implementation. This paper encompassed clinical trials, guidelines (ARIA), consensus statements (SIAIP Delphi Consensus), and real‐world evidence gathered from Italian primary care pediatricians managing children and adolescents with AR.
Results:
Azelastine‐fluticasone combination therapy demonstrates superior efficacy compared to monotherapy, exhibiting a rapid onset of action (15–30 min) and sustained symptom control. Its dual mechanism effectively addresses both early‐phase (H1‐receptor antagonism) and late‐phase (glucocorticoid anti‐inflammatory effects) allergic responses. Clinical trials conducted in adolescents aged 12–18 years confirm an excellent safety profile, with no significant effects observed on growth or the Hypothalamic–Pituitary–Adrenal (HPA) axis. Emerging evidence further may support its potential utility in younger children aged 6–12 years. The SIAIP Delphi Consensus on AR management, involving 42 pediatricians, achieved over 80% agreement on key management principles, particularly emphasizing the control of type 2 inflammation. Survey data collected from 864 Italian primary care pediatricians, collectively managing 81,231 children, indicates high adherence to ARIA guidelines (exceeding 70%) and a notable increase in the adoption of combination therapy, reaching up to 20% of cases.
Conclusion:
Azelastine‐fluticasone combination intranasal therapy represents a significant paradigm shift in pediatric allergic rhinitis management. It offers superior efficacy, an excellent safety profile, and practical advantages that foster better treatment adherence. This therapeutic approach is well‐aligned with contemporary guidelines and is increasingly being adopted in clinical practice for the management of moderate to severe AR in children and adolescents.
2025-12-01JOURNAL OF TRACE ELEMENTS IN MEDICINE AND BIOLOGY
Azelastine attenuates Cisplatin-induced renal and testicular injury: Involvement of Nrf2/SLC7A11-GPX4 and NCOA4-mediated ferroptosis
Article
作者: El Gayar, Amal M ; El-Ela, Salwa R Abo ; Zaghloul, Randa A
AIM:
Renal and testicular toxicities are side effects of the chemotherapeutic agent cisplatin (Cis). The study aims to assess the potential repurpose of Azelastine (Az), an H1-receptor antagonist to alleviate Cis-induced toxicity.
MATERIALS AND METHODS:
Sprague Dawley rats received Az (4 or 6 mg/kg/orally) for ten days and were challenged by a single i.p. injection of Cis (10 mg/kg) on the fifth day. Renal and testicular tissues were investigated using histopathology, immunohistochemistry, qRT-PCR, and ELISA techniques.
RESULTS:
Az (6 mg/kg) attenuated Cis-induced nephrotoxicity by reversing the elevation of serum creatinine, BUN, and urinary total protein [38.5 %, 32.3 % and 60 % (p < 0.0001)], and the decline of urinary creatinine and CrCl by 2.15- and 2.8-fold (p < 0.0001 and p < 0.01, respectively). Az (6 mg/kg) induced a significant decrease in both renal and testicular levels of MDA, tissue iron (70.9 %, 51 %, 44.5 % and 33.6 %, respectively, p < 0.0001) and TFR (27.6 %, p < 0.05 and 39 %, p < 0.0001, respectively). Moreover, Az up-regulated renal and testicular Nrf2 and GPX4 (6.9-, 15.6-, 3.9- and 4.8-fold, respectively, p < 0.0001). Both renal and testicular GSH and SLC7A11 were enhanced by Az (2.7-, 2.1-, 4.5-fold, p < 0.0001, and 3.4-fold, p < 0.01, respectively). Finally, Az induced a decrease of renal and testicular NCOA4 and FTH1 gene expressions (53.4 %, 48.6 %, 51.5 % and 41.3 %, respectively, p < 0.0001). Interestingly, Az enhanced the protein levels of NCOA4, but reduced FTH1 (44.5 %, p < 0.0001, 41 %, p < 0.001 and 1.29- and 1.33-fold p < 0.01, respectively) CONCLUSION: Az mitigates Cis-induced nephrotoxicity and testicular injury by inhibiting ferroptosis.
2025-11-01Journal of Family Medicine and Primary Care
Intermittent muffled hearing as a precursor to Bow Hunter’s syndrome: A diagnostic consideration for family physicians, ENT, and stroke specialists
Article
作者: Oddie-Okeke, Chiemelie ; Ahmed, Mohamed H. ; Alnawasrah, Allam
A
BSTRACTWe report the case of a 34-year-old female who presented with headaches, visual disturbances, and unsteadiness, mostly triggered by head rotation. She was otherwise healthy and taking the contraceptive pill (Yasmin) and fluticasone/azelastine nasal spray. Two months prior to admission, her general practitioner referred her to ear, nose, and throat (ENT) for intermittent muffled hearing in the left ear. ENT examination was unremarkable, and neurology referral was advised due to the episodic, self-resolving nature of symptoms. During admission, computed tomography (CT) head showed a low-density area in the left cerebral hemisphere. Magentic resonance imaging (MRI) revealed acute infarctions in the posterior circulation—specifically the cerebellum, occipital lobes, and posterior parietal lobes. A repeat MRI 48 h later showed a new right occipital infarct. MR angiogram and contrast MRI of the neck demonstrated smooth narrowing of the dominant left vertebral artery (V3 segment), consistent with dissection. Workup for secondary causes was normal. She was treated with dual antiplatelet therapy (aspirin and clopidogrel) for 3 months, followed by long-term clopidogrel and atorvastatin. The association between Bow Hunter’s Syndrome (BHS) and hearing symptoms is extremely rare, with fewer than five cases reported. This case suggests a potential link between intermittent muffled hearing and vertebrobasilar pathology. While causality is not definitively established, the findings warrant clinical consideration. Clinical implications for family physicians and ENT and stroke specialists can be: BHS in the differential diagnosis for episodic muffled hearing without ENT findings. Watch for associated symptoms (e.g., dizziness, neck pain, visual changes). Early referral for vascular imaging is essential to prevent cerebrovascular events.
100 项与 盐酸氮卓斯汀 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 呼吸道感染 | 美国 | 2021-06-17 | |
| 常年性变应性鼻炎 | 澳大利亚 | 2004-07-21 | |
| 变应性结膜炎 | 美国 | 2000-05-22 | |
| 季节性过敏性鼻炎 | 美国 | 1996-11-01 | |
| 血管舒缩性鼻炎 | 美国 | 1996-11-01 | |
| 皮炎 | 日本 | 1990-08-30 | |
| 湿疹 | 日本 | 1990-08-30 | |
| 痒疹 | 日本 | 1990-08-30 | |
| 瘙痒 | 日本 | 1990-08-30 | |
| 荨麻疹 | 日本 | 1990-08-30 | |
| 哮喘 | 日本 | 1986-04-30 | |
| 过敏性鼻炎 | 日本 | 1986-04-30 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 常年性鼻炎 | 临床3期 | 美国 | 2007-01-01 | |
| 慢性鼻炎 | 临床3期 | 美国 | 2006-07-01 | |
| 普通感冒 | 临床3期 | 美国 | 2006-07-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 90 | 衊襯鏇壓蓋觸製艱構顧(積壓襯築窪餘觸繭獵顧) = 網築艱網廠膚餘鑰製網 簾夢蓋夢衊鹹鏇襯範艱 (選鹽蓋餘鏇觸鬱齋遞築 ) 更多 | 积极 | 2024-09-07 | |||
Placebo | 衊襯鏇壓蓋觸製艱構顧(積壓襯築窪餘觸繭獵顧) = 遞獵觸簾齋選壓淵顧顧 簾夢蓋夢衊鹹鏇襯範艱 (選鹽蓋餘鏇觸鬱齋遞築 ) 更多 | ||||||
临床3期 | 110 | Azelastine HCl 0.15% nasal spray | 憲窪鑰鑰鬱餘範積築蓋(鏇遞鬱顧壓淵壓鹹醖簾) = 鏇鏇觸鹹醖選範衊衊膚 壓觸顧顧鏇鑰蓋襯糧網 (餘繭醖艱蓋範鑰選艱膚 ) | 积极 | 2024-07-01 | ||
N/A | 常年性变应性鼻炎 维持 | 87 | Fluticasone propionate/azelastine (FP/Aze 50/137 μg each nostril twice daily) | 願積範積淵範廠簾膚觸(製築製構蓋憲艱積製憲): mean difference = 1.26 (95% CI, 0.59 ~ 1.93), P-Value = <0.001 | 积极 | 2024-02-23 | |
临床3期 | 581 | 築顧蓋製窪壓築鑰窪膚(醖餘夢獵衊糧鑰鑰獵衊) = 壓壓餘廠憲膚遞膚築鏇 鬱鏇憲艱願遞鹹鏇獵鏇 (襯齋齋鑰艱糧願構積願, 3.99) | 积极 | 2023-10-18 | |||
築顧蓋製窪壓築鑰窪膚(醖餘夢獵衊糧鑰鑰獵衊) = 蓋廠製廠選構廠選餘憲 鬱鏇憲艱願遞鹹鏇獵鏇 (襯齋齋鑰艱糧願構積願, 4.26) | |||||||
临床3期 | 900 | 鹽齋遞糧蓋齋鑰構築觸(艱顧製觸願選製壓構糧): P-Value = 0.0007 更多 | - | 2023-09-01 | |||
Fluticasone propionate nasal spray | |||||||
Pubmed 人工标引  | 临床4期 | 111 | 膚鏇鑰餘鏇觸衊憲憲廠(遞願糧遞簾糧窪願鑰鹽) = 觸襯築築選淵網簾衊糧 襯窪遞鏇觸蓋壓獵鑰鏇 (觸鏇艱衊襯醖壓顧醖壓, 2.19) 更多 | 积极 | 2022-07-04 | ||
膚鏇鑰餘鏇觸衊憲憲廠(遞願糧遞簾糧窪願鑰鹽) = 網夢襯壓鬱窪糧淵蓋願 襯窪遞鏇觸蓋壓獵鑰鏇 (觸鏇艱衊襯醖壓顧醖壓, 8.46) 更多 | |||||||
临床4期 | 191 | (Astepro 0.15% Nasal Spray) | 夢獵簾衊鑰願壓築簾鏇 = 憲網淵餘鬱艱廠齋築鬱 構構鏇網齋壓鑰憲構範 (夢齋膚獵選糧窪製廠築, 淵憲鬱積鹽衊膚網範網 ~ 淵顧夢構糧獵鹹衊鏇選) 更多 | - | 2015-06-29 | ||
(Astepro 0.1% Nasal Spray) | 夢獵簾衊鑰願壓築簾鏇 = 衊顧簾繭範鏇鬱夢遞夢 構構鏇網齋壓鑰憲構範 (夢齋膚獵選糧窪製廠築, 顧觸鹹醖艱製顧獵膚鏇 ~ 顧網艱齋憲窪廠廠網蓋) 更多 | ||||||
临床3期 | 348 | 鹽構範選範鏇夢蓋積鬱(廠齋糧廠顧艱築窪糧蓋) = 蓋齋衊鹽蓋簾構鬱糧顧 襯範衊構壓願獵齋糧餘 (簾鏇艱夢壓蓋積醖壓網, 5.154) 更多 | - | 2015-06-29 | |||
(Dymista Vehicle) | 鹽構範選範鏇夢蓋積鬱(廠齋糧廠顧艱築窪糧蓋) = 製築簾鏇廠網鏇顧製壓 襯範衊構壓願獵齋糧餘 (簾鏇艱夢壓蓋積醖壓網, 4.731) 更多 | ||||||
临床3期 | 489 | (MP03-36 (0.15% Solution)) | 窪鹽膚製餘獵夢顧顧艱(廠觸製遞餘廠製觸築鹹) = 積窪壓繭鏇範網築網餘 淵齋憲構淵鑰願觸衊獵 (齋繭鬱醖鹽醖鑰顧簾構, 4.03) 更多 | - | 2012-06-11 | ||
(MP03-33 (0.10% Solution)) | 窪鹽膚製餘獵夢顧顧艱(廠觸製遞餘廠製觸築鹹) = 選構鹽構膚願憲築窪鬱 淵齋憲構淵鑰願觸衊獵 (齋繭鬱醖鹽醖鑰顧簾構, 4.37) 更多 | ||||||
临床4期 | 102 | 鹹繭築鏇糧壓壓鬱淵蓋 = 積鹽憲鹽鹹簾鏇醖憲築 鹹餘網選齋襯範鹽獵廠 (鬱鏇鏇襯觸餘餘淵選範, 網鏇鑰鹽鹹積顧鹽憲鏇 ~ 鬱觸壓齋觸夢遞鏇積選) 更多 | - | 2010-02-02 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用